Table 6

ORsa and 95% CIs for prostate cancer in relation to BMI and WHR, Shanghai, China

WHRbBMI
<20.5c20.5–22.8>22.8
N1/N2dOR95% CIN1/N2OR95% CIN1/N2OR95% CI
<0.87(21 /69)1.00(13 /50)0.80(0.36–1.76)(9 /35)0.78(0.32–1.90)
0.87–0.90(31 /53)1.91(0.98–3.72)(29 /57)1.67(0.85–3.26)(19 /44)1.41(0.67–2.94)
>0.90(26 /33)2.49(1.22–5.10)(33 /48)2.12(1.08–4.13)(50 /78)1.96(1.06–3.63)
<21.0e21.0–25.0>25.0
<0.87(25 /85)1.00(14 /57)0.80(0.38–1.69)(4 /12)1.16(0.34–3.95)
0.87–0.90(37 /72)1.78(0.98–3.25)(35 /67)1.83(0.99–3.38)(7 /15)1.59(0.58–4.40)
>0.90(34 /39)2.92(1.53–5.58)(56 /79)2.29(1.29–4.04)(19 /41)1.54(0.76–3.16)
  • a Adjusted for age, education, marital status, total calories, and BMI.

  • b Based on measured waist and hip circumferences at interview. Tertile levels among controls were used as the cutoffs.

  • c Based on self-report of usual adult height and weight at interview (kg/m2). Tertile levels among controls were used as the cutoffs.

  • d Number of cases (N1) and controls (N2).

  • e Arbitrary cutoffs.